Avalo Therapeutics (AVTX) Accumulated Depreciation & Amortization (2014 - 2025)
Avalo Therapeutics posted quarterly Accumulated Depreciation & Amortization of $253000.0 for Q4 2025, down 64.37% year-on-year from $710000.0 in Q4 2024, and down 64.37% on a QoQ basis from $710000.0 in Q4 2024.
Avalo Therapeutics (AVTX) has 12 years of Accumulated Depreciation & Amortization data on file, last reported at $253000.0 in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 64.37% year-over-year to $253000.0; the trailing twelve-month figure through Dec 2025 stood at $253000.0 (down 64.37% YoY), and the FY2025 full-year result was $253000.0, down 64.37% from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 stood at $253000.0, down from $710000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $710000.0 in Q4 2024 and bottomed at $253000.0 in Q4 2025.
- The 5-year median for Accumulated Depreciation & Amortization is $414000.0 (2022), against an average of $441000.0.
- The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization jumped 61.58%; it then plunged 64.37% in 2025.
- A 5-year view of Accumulated Depreciation & Amortization shows it stood at $286000.0 in 2021, then surged by 44.76% to $414000.0 in 2022, then soared by 30.92% to $542000.0 in 2023, then soared by 31.0% to $710000.0 in 2024, then slumped by 64.37% to $253000.0 in 2025.
- The last three Accumulated Depreciation & Amortization figures came in at $253000.0 (Q4 2025), $710000.0 (Q4 2024), and $542000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 253,000.00 |
| Dec 31, 2025 | 253,000.00 |
| Dec 31, 2024 | 710,000.00 |
| Dec 31, 2024 | 710,000.00 |
| Dec 31, 2023 | 542,000.00 |
| Dec 31, 2023 | 542,000.00 |
| Dec 31, 2022 | 414,000.00 |
| Dec 31, 2022 | 414,000.00 |
| Dec 31, 2021 | 286,000.00 |
| Dec 31, 2021 | 286,000.00 |
| Dec 31, 2020 | 177,000.00 |
| Dec 31, 2020 | 177,000.00 |
| Dec 31, 2019 | 3.88 Mn |
| Dec 31, 2019 | 3.88 Mn |
| Dec 31, 2018 | 4.55 Mn |
| Dec 31, 2018 | 4.55 Mn |
| Dec 31, 2017 | 425,476.00 |
| Dec 31, 2017 | 425,476.00 |
| Dec 31, 2016 | 26,856.00 |
| Dec 31, 2016 | 26,856.00 |
| Dec 31, 2015 | 23,508.00 |
| Dec 31, 2015 | 23,508.00 |
| Dec 31, 2014 | 37,328.00 |
| Dec 31, 2014 | 37,328.00 |